Viveve Medical (VIVE) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsShort InterestTrendsBuy This Stock VIVE vs. NMRD, UTRS, MOTS, DRTSW, ANZUW, ATAKW, BBLGW, HSCSW, BEATW, and LUCYWShould you be buying Viveve Medical stock or one of its competitors? The main competitors of Viveve Medical include Nemaura Medical (NMRD), Minerva Surgical (UTRS), Motus GI (MOTS), Alpha Tau Medical (DRTSW), Anzu Special Acquisition Corp I (ANZUW), Aurora Technology Acquisition (ATAKW), Bone Biologics (BBLGW), Heart Test Laboratories (HSCSW), HeartBeam (BEATW), and Innovative Eyewear (LUCYW). These companies are all part of the "medical equipment" industry. Viveve Medical vs. Its Competitors Nemaura Medical Minerva Surgical Motus GI Alpha Tau Medical Anzu Special Acquisition Corp I Aurora Technology Acquisition Bone Biologics Heart Test Laboratories HeartBeam Innovative Eyewear Viveve Medical (NASDAQ:VIVE) and Nemaura Medical (NASDAQ:NMRD) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, media sentiment, valuation, risk and dividends. Do insiders & institutionals have more ownership in VIVE or NMRD? 4.4% of Nemaura Medical shares are owned by institutional investors. 5.7% of Viveve Medical shares are owned by company insiders. Comparatively, 40.4% of Nemaura Medical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has higher earnings and valuation, VIVE or NMRD? Viveve Medical has higher revenue and earnings than Nemaura Medical. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioViveve Medical$6.83M0.00N/AN/AN/ANemaura Medical$3.02K0.00-$14.14M-$0.39N/A Which has more risk & volatility, VIVE or NMRD? Viveve Medical has a beta of 0.11, suggesting that its share price is 89% less volatile than the S&P 500. Comparatively, Nemaura Medical has a beta of 0.6, suggesting that its share price is 40% less volatile than the S&P 500. Does the media refer more to VIVE or NMRD? In the previous week, Viveve Medical's average media sentiment score of 0.00 equaled Nemaura Medical'saverage media sentiment score. Company Overall Sentiment Viveve Medical Neutral Nemaura Medical Neutral Is VIVE or NMRD more profitable? Company Net Margins Return on Equity Return on Assets Viveve MedicalN/A N/A N/A Nemaura Medical N/A N/A N/A SummaryNemaura Medical beats Viveve Medical on 3 of the 4 factors compared between the two stocks. Get Viveve Medical News Delivered to You Automatically Sign up to receive the latest news and ratings for VIVE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VIVE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VIVE vs. The Competition Export to ExcelMetricViveve MedicalElectromedical equipment IndustryMedical SectorNASDAQ ExchangeMarket Cap$1K$39.56M$5.76B$9.58BDividend YieldN/AN/A4.41%4.10%P/E RatioN/A3.4131.1026.04Price / SalesN/A250.60435.26103.29Price / CashN/A41.3637.7358.48Price / BookN/A2.259.536.61Net IncomeN/A-$2.66M$3.26B$265.56M Viveve Medical Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VIVEViveve MedicalN/AN/AN/AN/A$1K$6.83M0.0070NMRDNemaura Medical1.2185 of 5 starsN/AN/AN/A$4K$3.02K0.0040UTRSMinerva SurgicalN/AN/AN/AN/A$1K$51.69M0.00160MOTSMotus GI0.2981 of 5 starsN/AN/A-99.7%$1K$319K0.0030DRTSWAlpha Tau MedicalN/A$0.28+2.3%N/A+49.5%$0.00N/A0.0080ANZUWAnzu Special Acquisition Corp IN/A$0.04-21.1%N/A-41.6%$0.00N/A0.002Gap DownATAKWAurora Technology AcquisitionN/A$0.02flatN/A-62.5%$0.00N/A0.00N/AHigh Trading VolumeBBLGWBone BiologicsN/A$10.79-28.1%N/AN/A$0.00N/A0.002Gap DownHSCSWHeart Test LaboratoriesN/A$0.12-32.7%N/AN/A$0.00$4.35K0.0010BEATWHeartBeamN/A$0.28+0.2%N/A-37.2%$0.00N/A0.005Gap DownLUCYWInnovative EyewearN/A$0.08-12.7%N/A+111.8%$0.00$1.71M0.009 Related Companies and Tools Related Companies Nemaura Medical Competitors Minerva Surgical Competitors Motus GI Competitors Alpha Tau Medical Competitors Anzu Special Acquisition Corp I Competitors Aurora Technology Acquisition Competitors Bone Biologics Competitors Heart Test Laboratories Competitors HeartBeam Competitors Innovative Eyewear Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VIVE) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viveve Medical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viveve Medical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access